The Moderna Vaccine IndexThese companies are selected for composition "Moderna Vaccine" because
1.developed the vaccine
2.suppliers
3.distribution chain
Weights are calculated by relative market cap.
Next report date
Report period
Q1 2024
EPS estimate
—
Revenue estimate
153.70 MEUR
3.22EUR
170.34 MEUR
829.51 MEUR
17.95 M
About LABORATORIOS FARMACEUTICOS ROVI S.A.
Sector
CEO
Juan López-Belmonte Encina
Headquarters
Madrid
Website
Employees (FY)
2.11 K
Founded
1946
ISIN
ES0157261019
FIGI
BBG000RL1KB5
Laboratorios Farmaceúticos Rovi SA engages in the research, development, manufacture, and marketing of small molecule and specialty biologic drugs. It operates through the following business segments: Manufacturing, Marketing, and Other. The Manufacturing segment obtains its income from service contracts that relate to the finalization of the pharmaceutical product production process for external entities and the manufacture of products to be subsequently marketed by other group companies. The Marketing segment purchases and sells pharmaceutical products. The Other segment includes other services, research, and development activities that are not significant for the group. The company was founded on December 21, 1946 and is headquartered in Madrid, Spain.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
Depending on the exchange, the stock ticker may vary. For instance, on SWB exchange LABORATORIOS FARMACEUTICOS ROVI SA stocks are traded under the ticker 41L.
LABORATORIOS FARMACEUTICOS ROVI SA is going to release the next earnings report on May 8, 2024. Keep track of upcoming events with our Earnings Calendar.
41L earnings for the last quarter are 0.15 EUR per share, whereas the estimation was 0.11 EUR resulting in a 36.36% surprise. The estimated earnings for the next quarter are 0.61 EUR per share. See more details about LABORATORIOS FARMACEUTICOS ROVI SA earnings.
LABORATORIOS FARMACEUTICOS ROVI SA revenue for the last quarter amounts to 214.05 M EUR despite the estimated figure of 210.56 M EUR. In the next quarter revenue is expected to reach 223.60 M EUR.
Yes, you can track LABORATORIOS FARMACEUTICOS ROVI SA financials in yearly and quarterly reports right on TradingView.
41L net income for the last quarter is 51.51 M EUR, while the quarter before that showed 52.18 M EUR of net income which accounts for −1.29% change. Track more LABORATORIOS FARMACEUTICOS ROVI SA financial stats to get the full picture.
Yes, 41L dividends are paid annually. The last dividend per share was 1.05 EUR. As of today, Dividend Yield (TTM)% is 1.24%. Tracking LABORATORIOS FARMACEUTICOS ROVI SA dividends might help you take more informed decisions.
Like other stocks, 41L shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade LABORATORIOS FARMACEUTICOS ROVI SA stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 27, 2024, the company has 2.11 K employees. See our rating of the largest employees — is LABORATORIOS FARMACEUTICOS ROVI SA on this list?
We've gathered analysts' opinions on LABORATORIOS FARMACEUTICOS ROVI SA future price: according to them, 41L price has a max estimate of 93.00 EUR and a min estimate of 60.00 EUR. Read a more detailed LABORATORIOS FARMACEUTICOS ROVI SA forecast: see what analysts think of LABORATORIOS FARMACEUTICOS ROVI SA and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. LABORATORIOS FARMACEUTICOS ROVI SA EBITDA is 243.80 M EUR, and current EBITDA margin is 29.39%. See more stats in LABORATORIOS FARMACEUTICOS ROVI SA financial statements.